2024

1. A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies

   British Journal of Haematology

2. An atlas of cells in the human tonsil

   Immunity, Vol. 57, Núm. 2, pp. 379-399.e18

3. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

   Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

4. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

   JHEP Reports, Vol. 6, Núm. 1

5. Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease

   Journal of Magnetic Resonance Imaging, Vol. 60, Núm. 2, pp. 534-547

6. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

   Haematologica

7. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

   Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

8. Biomaterials-Based Antioxidant Strategies for the Treatment of Oxidative Stress Diseases

   Biomimetics, Vol. 9, Núm. 1

9. Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma

   Scientific Reports, Vol. 14, Núm. 1

10. CD137 (4-1BB) and T-Lymphocyte Exhaustion

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 3971-3973

11. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

12. Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry

    STAR Protocols, Vol. 5, Núm. 1

13. Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 10, pp. 2910-2921

14. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

15. Deciphering the Role of Post-Translational Modifications and Cellular Location of Hepatitis Delta Virus (HDV) Antigens in HDV-Mediated Liver Damage in Mice

    Viruses, Vol. 16, Núm. 3

16. Dendritic Cells in Cancer Immunology and Immunotherapy

    Cancers, Vol. 16, Núm. 5

17. Double-Stranded RNA to Mimic Viral Infection for Cancer Immunotherapy

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 16, pp. 3355-3357

18. Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

19. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

20. Experimentally-guided in silico design of engineered heart tissues to improve cardiac electrical function after myocardial infarction

    Computers in Biology and Medicine, Vol. 171